Highlights Adicet Bio, Inc.

Equities

ACET

US0070021086

Market Closed - Nasdaq Other stock markets 21:00:00 14/05/2024 BST			5-day change	1st Jan Change
1.33 ^USD	-7.64%		-23.12%	-29.63%

05-14	Adicet Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-22	Adicet Bio, Inc. Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the ASGCT 27th Annual Meeting	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Adicet Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Adicet Bio, Inc. Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the ASGCT 27th Annual Meeting	04-22	CI
Adicet Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
Adicet Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-19	CI
Adicet Bio, Inc. Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study At the 65Th American Society of Hematology Annual Meeting	12-10	CI
Adicet Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
Adicet Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23	CI
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkinâ€™s Lymphoma	26/06/23	CI
Adicet Bio, Inc. Presents Positive Preclinical Data on ADI-270 At the American Society of Gene and Cell Therapy 26Th Annual Meeting	18/05/23	CI
Adicet Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/05/23	CI
Adicet Bio, Inc. Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma	10/12/22	CI
Adicet Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	08/11/22	CI
Adicet Bio, Inc. Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma	03/11/22	CI
Adicet Bio's Q2 Net Loss Widens	10/08/22	MT
Adicet Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	10/08/22	CI
Adicet Bio, Inc. Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting	06/06/22	CI
Adicet Bio, Inc. Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma	26/05/22	CI
Adicet Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	12/05/22	CI
Adicet Bio, Inc. Presents Preclinical Data at ISCT Annual Meeting Highlighting Potential Advantages of Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta Car T Cell Therapy Targeting CD20 for B Cell Malignancies	05/05/22	CI
Adicet Bio, Inc. Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology Annual Meeting	27/04/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Adicet Bio, Inc.

Equities

ACET

US0070021086

Highlights

Filters